Purpose: This study compared the characteristics of a population of Swedish patients in forensic psychiatric care in the year 2010 and 2018, with the goal of identifying similarities and differences in sociodemographic and clinical outcomes during the study period.
Findings: Significant changes in patient characteristics and treatment aspects were found, although similarities between the years were more common. Schizophrenia, schizotypal and delusional disorders were the most predominant primary diagnoses characterizing forensic psychiatric patients. From 2010 to 2018 there was also a development in care conditions supporting a shift from inpatient to outpatient care and from first-generation antipsychotic/neuroleptic to second-generation antipsychotics/atypical antipsychotics. More liberty restrictive such as physical restraints and forcible medication diminished while less restrictive coercive measures increased. There was also a decrease in the length of stay in forensic psychiatric care among those treated 2018 compared to those treated 2010, something that emerged as particularly discernible among male patients.
Conclusion: In conclusion, the results from this study illustrate the similarities among a Swedish forensic psychiatric population between the years of 2010 and 2018, while also reflecting some changes in patient characteristics and clinical practice during the study period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijlp.2021.101715 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force.
Eur Psychiatry
January 2025
Mental Health Services Noord-Holland-Noord, Alkmaar, the Netherlands; Dutch Clozapine Collaboration Group, Alkmaar, the Netherlands.
Medical Termination of Pregnancy: Law and Controversies in the United States and Australia.
J Law Med
November 2024
Barrister, Castan Chambers, Melbourne, Australia; Professor of Law and Professorial Fellow in Psychiatry, University of Melbourne; Honorary Professor of Forensic Medicine, Monash; Adjunct Professor, Southern Cross University.
This editorial reviews the changes over two decades in the United States and Australia in relation to the law governing access to drugs enabling medical termination of pregnancy. It also scrutinises three contentious decisions by the United States Supreme Court between 2022 and 2024 in relation to abortion. It argues that the receptive environment in the United States Supreme Court, as it is currently constituted, to challenges to the lawfulness of terminations of pregnancy and abortion medications is likely to inspire comparable challenges as part of the "Abortion Wars" in other countries, including Australia.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Background: Parkinson's disease and dementia with Lewy bodies are characterized by abnormal iron deposition in the substantia nigra, which can be measured with quantitative susceptibility mapping (QSM) on MRI. However, neuropathologic validation of the increased QSM in the substantia nigra associated with Lewy body disease (LBD) is lacking. We compared substantia nigra QSM on antemortem MRI between patients with and without Lewy-related pathology which was confirmed by autopsy in all cases.
View Article and Find Full Text PDFBackground: Synuclein Aggregate Assays (SAA) in cerebrospinal fluid (CSF) and in skin biopsy have been shown to successfully identify underlying synuclein (Lewy body) pathology in patients with Parkinson's disease. Data in Lewy Body Dementia (LBD) is limited, particularly with pathologic confirmation and staging of underlying Lewy body pathology, and other co-pathologies.
Method: Utilizing data and biofluids from participants in the U.
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Background: Phosphorylated-tau (p-tau) biomarkers are typically specific for Alzheimer's disease (AD) and are less elevated in the cerebrospinal fluid (CSF) of frontotemporal lobar degeneration (FTLD) type tau (FTLD-tau). FTLD is a pathologically and clinically heterogenous neurodegenerative disorder, and we currently lack biomarkers to differentiate the two major pathological subtypes 1) FTLD-tau, where pathological tau aggregation is observed or 2) FTLD-TDP, where TAR-DNA binding protein 43 (TDP-43) is linked with the disease development and progression. Because FTD clinical phenotype does not predict pathology, biomarkers sensitive to FTLD-tau are needed to provide a biological diagnosis in life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!